Reckitt Benckiser – Rising Costs Hits Profits

0
Reckitt Benckiser – Rising Costs Hits Profits
geralt / Pixabay

First half like-for-like (LFL) revenue came in at £6.3bn, excluding the for sale Chinese Infant Nutrition business, a 3.7% annual increase. Changes in pricing and sales mix were behind revenue growth, though volumes also rose slightly. Operating profits declined 5% to £1.4bn, reflecting increased investment and cost inflation.

Get The Full Henry Singleton Series in PDF

Get the entire 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues

Q2 2021 hedge fund letters, conferences and more

The group plans price rises in the second half to cope with the rising costs but expects full year margins to decline between 0.4 and 0.9 percentage points.

SALT New York: Canyon, Mudrick, Fortress And Sculptor On Finding Distressed Value

At the 2021 SALT New York conference, which was held earlier this week, one of the panels on the main stage discussed the best macro shifts coming out of the pandemic and investing in value amid distress. The panel featured: Todd Lemkin, the chief investment officer of Canyon Partners; Peter Wallach, the managing director and Read More

The board recommended an interim dividend of 73p.

The shares were down 9.5% following the announcement

Reckitt Benckiser Is Planning To Cope With Cost Inflation

"Costs were on the rise at Reckitt Benckiser Group Plc (LON:RKT), causing a 5% slide in profits at the half.  Moving forward Reckitt is planning to cope with cost inflation with price hikes and productivity improvements, but it won’t be enough to offset the damage that’s been done. The group now expects margins to come in 0.4-0.9 percentage points lower at the full year.

While costs rose, revenue only grew modestly. Reckitt was up against tough comparisons across several product categories like Dettol and Vitamins, Minerals & Supplements as it lapped quarters of extremely strong pandemic-fuelled demand. It didn’t help that a weak cold and flu season meant demand for its more profitable OTC products was lagging.

All told, Reckitt’s half-year results were disappointing, sending shares on a nose dive. But a look beyond the headline numbers suggests this could be somewhat of an overreaction.

Compared to 2019 levels, Reckitt’s doing relatively well. A drop-off from the Covid-related frenzy that ensued last year was inevitable, but some of that demand has been sticky. Lysol, for example has seen its sales rise over 100% from pre-pandemic levels. Plus, cold-and-flu products are starting to see things pick up, particularly in US states where masks are no longer required. This trend could start to snowball across other markets as Covid restrictions ease heading into the winter.

The group’s also about to offload its troubled Chinese Infant Nutrition business, a welcome development in our eyes. This will leave it leaner and better able to capitalise on its more profitable brands.

This may be a case of the market failing to see the forest through the trees. Reckitt’s in the midst of a transition and at the same time it’s coping with a come-down from pandemic highs. But if the group can hold on to most of the customers it snapped up last year while still growing the arms of the business that struggled during Covid, we think it could be in a strong position to deliver long-term growth."

Article by Laura Hoy, Equity Analyst at Hargreaves Lansdown


About Hargreaves Lansdown

Over 1.6 million clients trust us with £132.9 billion (as at 30 April 2021), making us the UK’s largest digital wealth management service. More than 98% of client activity is done through our digital channels and over 600,000 access our mobile app each month.

Updated on

No posts to display